Professor

Research Areas

Chemical Biology; Medicinal Chemistry

Education & Positions

University Education:

1995-1998      Graduate School, Beijing Medical University, Major in Medicinal Chemistry, China. PhD.

1982-1987      School of Pharmaceutical Sciences, Beijing Medical University, China. BA.

Professional Experience:

2010-date       AssociateDirector, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University

2008-date       Professor of Medicinal Chemistry, School of Pharmaceutical Sciences, State Key Laboratory of Natural & Biomimetic Drugs, Peking University

2002-2008      Associate Professor of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University

2000-2002      Research Associate, School of Pharmacy, University of Georgia, USA

1999-2000      Associate Professor, School of Pharmaceutical Sciences, Beijing Medical University

1992-1995      Lecturer, School of Pharmaceutical Sciences, Beijing Medical University

1987-1992      Assistant, School of Pharmaceutical Sciences, Beijing Medical University

Faculty Accolades

2009    Science and Technology Award, Second Prize, awarded by The Ministry of Education, China

2004    Natural Science Award, Second Prize, Ministry of Science and Technology, China

2002    Science and Technology Award, Second Prize, awarded by The Ministry of Education, China

1998    Science and Technology Award, First Prize, awarded by The Ministry of Education, China

Research Interests

1. Modified antisense oligonucleotides and siRNA drugs; 2. New techniques based on aptamers for disease detection; 3. Chemical biology research of cyclic nucleotide messengers; 4. Nucleoside antiviral drugs. Recently, his group has made significant research progress in the design and screening of breast and liver cancer aptamers, controllable synthesis and application of fluorine-incorporated organic functional oligonucleotides, frontier research of siRNA and antisense ODN technology including isonucleoside modification, peptide-conjugation and neutral nucleobase-lipids as transfection reagent, application of inhibiting liver cancer metastasis by chemically modified miRNA, and ribonucleoside monophosphate antiviral drugs.

Publications:

Over 150 in refereed journals. Selected Publications:

1. Annealing novel nucleobase-lipids with oligonucleotides or plasmid DNA based on H-bonding or π-π interaction: assemblies and transfections, Y Ma, YJ Zhu, C Wang, DL Pan, S Liu, MY Yang, ZP Xiao, XT Yang, WT Zhao, XY Zhou, YD Li, YF Pan, J Sun, SH Wang, Z Guan, LH Zhang, ZJ Yang^*, Biomaterials , 2018, 178 , 147-157.

2. Delivery pathway regulation of 3',3'-bis-peptide-siRNA conjugate by nano-carrier architecture engineering, J Sun, C Qiu, YP Diao, W Wei, HW Jin, Y Zheng, JC Wang^*, LH Zhang, ZJ Yang^*, Mol. Ther.-Nucleic Acids , 2018, 10, 75-90.

3. Bioactivity of D-/L-isonucleoside- and 2￠-deoxyinosine-incorporated aptamer AS1411s and their regulation on DNA replication and miRNA expression, XM Fan, LD Sun, KF Li, XT Yang, BB Cai, YF Zhang, YJ Zhu, Y Ma, Z Guan, Y Wu, LH Zhang, ZJ Yang^*, Mol. Ther.-Nucleic Acids , 2017, 9 , 218-229.

4. Mechanistic study of the roles of disulfide-bridge in H-shape gemini-like cationic lipid based siRNA delivery, XF Ma, J Sun, YF Wu, Y Zheng, MZ Yu, C Qiu, XW Pei, L Wei, YJ Niu, WH Pang, ZJ Yang^*, JC Wang^*, Q Zhang, J. Control. Release ,2016, 235, 99-111.

5. DL Pan, J Sun, HW Jin, YT Li, LY Li, Y. Wu, LH Zhang, ZJ Yang^*, Supramolecular assemblies of novel aminonucleoside phospholipids and their bonding to nucleic acids, Chem. Commun. , 2015, 51 , 469-472.

6. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas, LY Li, JJ Hou, XJ Liu, YJ Guo, Y Wu^*, LH Zhang, ZJ Yang^*, Biomaterials , 2014, 35 , 3840-3850.